In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Mesoblast enters into $75mm credit facility with Hercules Capital

Executive Summary

Mesoblast Ltd. (allogenic cell therapy platform) entered into a four-year $75mm credit facility with Hercules Capital with $35mm drawn down at closing. An additional $15mm may be drawn on or before Q4 2018, and the final $25mm may be drawn on or before Q3 2019. The loan bears an interest rate of 9.45% per year with interest payments required over the first 30 months of the loan. Proceeds will be used to fund commercialization of MSC-100-IV (remestemcel-L) in children with steroid refractory acute graft versus host disease and to further the company's late stage pipeline including MPC-150-IM in patients with Class II/III advanced chronic heart failure, and in end-stage Class III/IV heart failure patients with left ventricular assist devices, and MPC-06-ID in patients with chronic low back pain due to degenerative disc disease.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Nonconvertible Debt
    • Venture Financing

Related Companies